For mothers with opioid use disorder (OUD), treatment with buprenorphine in pregnancy is associated with improved maternal and infant outcomes.

Patients with at least 5 comorbidities had worsened pain and functional scores compared with patients with 3 comorbidities at 12 months following TKA.

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Among patients with acute LBP, use of nonpharmacologic therapy was associated with reduced risk for overdose-related hospitalizations.

Urinary incontinence is not associated with moderate-to-vigorous physical activity (MVPA) classification, but is associated with cardiovascular disease (CVD) risk factors and comorbidity.

Metformin and SGLT2 inhibitors are associated with similar rates of incident gout among patients with type 2 diabetes.

Combination rituximab and IVIG therapy may be a viable treatment option for patients with refractory autoimmune diseases, though the quality of evidence is low.

Patients with vs without RA have a higher risk for avoidable hospitalizations for ambulatory care sensitive conditions, particularly heart failure and pulmonary edema.

Earlier PT initiation and more frequent sessions are associated with a reduced risk for future IAT use among individuals with knee OA.

Sex hormone decreases over time were associated with decreases in lean mass and physical performance metrics among older men.

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

The FDA has communicated to Stealth BioTherapeutics that it would not meet elamipretide’s PDUFA target date for the treatment of Barth syndrome.